File Download

There are no files associated with this item.

Supplementary

Conference Paper: KEYNOTE-495/KeyImPaCT: Phase 2 biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non–small cell lung cancer

TitleKEYNOTE-495/KeyImPaCT: Phase 2 biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non–small cell lung cancer
Authors
Issue Date2019
Citation
AACR 2019, Atlanta, USA (28 March - 3 Apr 2019) How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/279532

 

DC FieldValueLanguage
dc.contributor.authorGutierrez, M-
dc.contributor.authorHellmann, MD-
dc.contributor.authorGubens, MD-
dc.contributor.authorAggarwal, CA-
dc.contributor.authorTan, DSW-
dc.contributor.authorFilip, E-
dc.contributor.authorChiu, WYJ-
dc.contributor.authorLee, JS-
dc.contributor.authorYang, JCH-
dc.contributor.authorGaron, EB-
dc.date.accessioned2019-11-01T07:19:09Z-
dc.date.available2019-11-01T07:19:09Z-
dc.date.issued2019-
dc.identifier.citationAACR 2019, Atlanta, USA (28 March - 3 Apr 2019)-
dc.identifier.urihttp://hdl.handle.net/10722/279532-
dc.languageeng-
dc.relation.ispartofAACR 2019, Atlanta, USA (28 March - 3 Apr 2019)-
dc.titleKEYNOTE-495/KeyImPaCT: Phase 2 biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non–small cell lung cancer-
dc.typeConference_Paper-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.identifier.hkuros308519-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats